| Code | CSB-RA004775MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Bertilimumab, targeting CCL11 (eotaxin-1), a potent CC chemokine family member that plays a central role in eosinophil recruitment and activation. CCL11 binds primarily to the CCR3 receptor and functions as a key mediator of allergic inflammation by directing eosinophil trafficking to sites of inflammation. Elevated CCL11 levels are associated with various pathological conditions including allergic diseases, asthma, eosinophilic esophagitis, inflammatory bowel disease, and certain fibrotic disorders. Additionally, CCL11 has been implicated in age-related cognitive decline and neuroinflammatory processes.
Bertilimumab is a humanized IgG4 monoclonal antibody that was investigated in clinical trials for conditions such as ulcerative colitis and bullous pemphigoid due to its ability to neutralize CCL11 activity. This biosimilar antibody provides researchers with a valuable tool for investigating CCL11-mediated pathways, studying eosinophil biology, exploring mechanisms of allergic and inflammatory diseases, and evaluating potential therapeutic interventions targeting the CCL11-CCR3 axis in preclinical models.
There are currently no reviews for this product.